Skip to main content

Accelerating the Development of New Drugs and Diagnostics Maximizing the Impact of the Cures Acceleration Network: Workshop Summary (2012) / Chapter Skim
Currently Skimming:

6 Final Reflections on Ways to Maximize the Goals of CAN
Pages 65-70

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 65...
... · Personal passion and a tolerance of failure will be important components of CAN's success. · Possible ways to define success of CAN include -- installation of NCATS staff with therapeutics development expertise; -- implementation of milestone-based contracts and increased accountability; -- establishment of greater collaboration and robust public­private partnerships; -- advancement of regulatory science and tools for drug development tools; and -- development of cures: new therapeutics and diagnostics.
Read the entire page →
From page 66...
... "With all due respect, [designing] a Mach 20 aircraft is easy compared to a typical drug." Ninety-nine out of 100 drug development projects fail to make a significant medical impact.
Read the entire page →
From page 67...
... Mimura emphasized the point that changes anywhere in an inter connected ecosystem can drive change in the entire system. For example, very early-stage research aimed at a commercial product typically is not ready to be picked up by biotechnology companies or pharmaceutical companies.
Read the entire page →
From page 68...
... The rest of NIH still has $30 billion to do 4 This section is based on remarks by Robert Califf, Professor of Medicine, Duke University Medical Center. 5 This section is based on remarks by Sudip Parikh, Vice President of Health Policy, and Managing Director, Centers for Public Health Research and Evaluation, Battelle Memorial Institute.
Read the entire page →
From page 69...
... "We are infusing that into the brains and the hearts of everybody who works with us. The question is now whether or not we can deliver on showing that CAN can cut through red tape, create culture change, and create new tools and new processes that will make a demonstrable difference." The proper balance between developing tools and supporting specific projects remains uncertain and will need to be addressed by the CAN Board, she said.
Read the entire page →
From page 70...
... "We have an important duty to make sure that these dollars are spent well," she said. She commented that the input of the workshop was extremely beneficial.
Read the entire page →

Key Terms

  • drug development
  • industry research
  • cultural change
  • kathy hudson
  • projects fail

  • battelle memorial
  • senior statistical
  • vice chancellor
  • statistical advisor
  • sudip parikh

  • carol mimura
  • vertex pharmaceuticals
  • joshua boger
  • assistant vice
  • memorial institute

  • robert califf
  • research alliances
  • specific diseases
  • managing director
  • academic investigators

  • delivered closing
  • pharmaceutical companies
  • funding initially
  • ncats staff
  • typical reason

  • inter connected
  • create culture
  • significant medical
  • catalytic role
  • development tools


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.